Use of fluoroquinolones for the treatment of TB: 8 years of experience

J Antimicrob Chemother. 2015 Nov;70(11):3166-7. doi: 10.1093/jac/dkv227. Epub 2015 Aug 9.

Authors

H Ferrand¹, A-L Blanc-Gruyelle², M Amsilli³, X Lemaire², E Papot³, E Papy⁴, J Bervar⁵, E Senneville⁶, E Bouvet³, Y Yazdanpanah³

Affiliations

¹ Service de Maladies Infectieuses, Hôpital Bichat, Paris, France [email protected].
² Médecine Polyvalente et Maladies Infectieuses, Centre Hospitalier de Douai, Douai, France.
³ Service de Maladies Infectieuses, Hôpital Bichat, Paris, France.
⁴ Pharmacie, Hôpital Bichat, Paris, France.
⁵ Service de Pneumologie, Hôpital Calmette, Lille, France.
⁶ Service de Maladies Infectieuses, Hôpital Dron, Tourcoing, France.

PMID: 26260132
DOI: 10.1093/jac/dkv227

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antitubercular Agents / adverse effects
Antitubercular Agents / therapeutic use*
Drug-Related Side Effects and Adverse Reactions / epidemiology
Drug-Related Side Effects and Adverse Reactions / pathology
Female
Fluoroquinolones / adverse effects
Fluoroquinolones / therapeutic use*
France
Hospitals
Humans
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Tuberculosis / drug therapy*
Young Adult

Substances

Antitubercular Agents
Fluoroquinolones